Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diphtheria Toxin | 11 | 2009 | 26 | 1.720 |
Why?
|
| Sepsis | 8 | 2016 | 161 | 1.490 |
Why?
|
| Sirtuin 1 | 5 | 2014 | 37 | 1.470 |
Why?
|
| Recombinant Fusion Proteins | 11 | 2005 | 104 | 1.450 |
Why?
|
| Energy Metabolism | 5 | 2019 | 147 | 1.020 |
Why?
|
| Glioblastoma | 6 | 2009 | 155 | 0.990 |
Why?
|
| Epidermal Growth Factor | 5 | 2005 | 27 | 0.970 |
Why?
|
| Brain Neoplasms | 5 | 2009 | 637 | 0.790 |
Why?
|
| Interleukin-13 | 3 | 2009 | 28 | 0.770 |
Why?
|
| Inflammation | 7 | 2019 | 529 | 0.720 |
Why?
|
| Monocytes | 3 | 2019 | 127 | 0.700 |
Why?
|
| Epigenesis, Genetic | 4 | 2014 | 104 | 0.640 |
Why?
|
| Transcription Factor RelB | 4 | 2014 | 26 | 0.620 |
Why?
|
| Sirtuins | 2 | 2016 | 20 | 0.540 |
Why?
|
| Endotoxins | 4 | 2014 | 37 | 0.510 |
Why?
|
| Sirtuin 3 | 1 | 2014 | 3 | 0.490 |
Why?
|
| Cell Nucleus | 1 | 2014 | 108 | 0.460 |
Why?
|
| Drug Resistance | 2 | 2011 | 38 | 0.460 |
Why?
|
| Exotoxins | 2 | 2003 | 13 | 0.450 |
Why?
|
| Mitochondria | 1 | 2014 | 185 | 0.430 |
Why?
|
| Signal Transduction | 3 | 2016 | 680 | 0.430 |
Why?
|
| Interleukin-3 | 4 | 2004 | 11 | 0.420 |
Why?
|
| Fatty Acids | 1 | 2012 | 98 | 0.390 |
Why?
|
| Antineoplastic Agents | 4 | 2004 | 606 | 0.390 |
Why?
|
| Glucose | 1 | 2012 | 174 | 0.380 |
Why?
|
| Promoter Regions, Genetic | 2 | 2011 | 208 | 0.370 |
Why?
|
| Cytotoxins | 1 | 2009 | 13 | 0.330 |
Why?
|
| Cell Hypoxia | 1 | 2009 | 41 | 0.320 |
Why?
|
| Cell Line | 4 | 2014 | 435 | 0.310 |
Why?
|
| Oxygen | 1 | 2009 | 142 | 0.300 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2012 | 40 | 0.290 |
Why?
|
| Lipopolysaccharides | 4 | 2019 | 109 | 0.280 |
Why?
|
| Animals | 15 | 2016 | 7510 | 0.270 |
Why?
|
| Receptors, Interleukin-3 | 3 | 2004 | 5 | 0.260 |
Why?
|
| Glioma | 2 | 2005 | 136 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 210 | 0.250 |
Why?
|
| Mice | 7 | 2014 | 2474 | 0.250 |
Why?
|
| Humans | 23 | 2019 | 32082 | 0.240 |
Why?
|
| Cell Line, Tumor | 6 | 2009 | 725 | 0.240 |
Why?
|
| NAD | 3 | 2016 | 27 | 0.230 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2003 | 4 | 0.230 |
Why?
|
| Glycolysis | 2 | 2014 | 20 | 0.230 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 493 | 0.220 |
Why?
|
| Leukocytes | 3 | 2014 | 57 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 3 | 2014 | 764 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 4 | 2004 | 171 | 0.180 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2005 | 22 | 0.170 |
Why?
|
| Receptors, Interleukin | 3 | 2003 | 16 | 0.170 |
Why?
|
| MicroRNAs | 2 | 2011 | 180 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 2 | 2015 | 23 | 0.150 |
Why?
|
| Spleen | 2 | 2014 | 87 | 0.150 |
Why?
|
| Histones | 3 | 2011 | 53 | 0.140 |
Why?
|
| Brain | 1 | 2003 | 948 | 0.130 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 137 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2004 | 58 | 0.120 |
Why?
|
| Protein Biosynthesis | 2 | 2015 | 40 | 0.120 |
Why?
|
| RNA-Binding Proteins | 2 | 2012 | 68 | 0.120 |
Why?
|
| Immunity | 1 | 2014 | 20 | 0.120 |
Why?
|
| Transcription Factor RelA | 2 | 2011 | 22 | 0.120 |
Why?
|
| Gene Silencing | 2 | 2011 | 48 | 0.120 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 154 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 1020 | 0.110 |
Why?
|
| Receptors, Interleukin-13 | 2 | 2003 | 9 | 0.110 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 2 | 2003 | 10 | 0.110 |
Why?
|
| Heterochromatin | 2 | 2011 | 12 | 0.110 |
Why?
|
| Mice, Knockout | 1 | 2014 | 443 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2003 | 185 | 0.110 |
Why?
|
| Monocyte-Macrophage Precursor Cells | 1 | 2012 | 3 | 0.100 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2012 | 7 | 0.100 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2012 | 13 | 0.100 |
Why?
|
| Phenotype | 1 | 2014 | 632 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 23 | 0.100 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 33 | 0.100 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 55 | 0.100 |
Why?
|
| Alzheimer Disease | 1 | 2016 | 327 | 0.100 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 268 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2012 | 136 | 0.100 |
Why?
|
| Protein Stability | 1 | 2011 | 25 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2012 | 181 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2011 | 42 | 0.090 |
Why?
|
| Cytokines | 1 | 2012 | 256 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 3 | 2005 | 62 | 0.090 |
Why?
|
| Nucleosomes | 1 | 2009 | 4 | 0.090 |
Why?
|
| Macrophages | 1 | 2011 | 188 | 0.080 |
Why?
|
| Furin | 1 | 2009 | 3 | 0.080 |
Why?
|
| Immunotoxins | 1 | 2009 | 17 | 0.080 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2009 | 11 | 0.080 |
Why?
|
| Aging | 1 | 2015 | 943 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 1128 | 0.070 |
Why?
|
| Leukemia, Myeloid | 2 | 2004 | 24 | 0.070 |
Why?
|
| Metabolome | 2 | 2019 | 36 | 0.070 |
Why?
|
| Acute Disease | 2 | 2004 | 252 | 0.070 |
Why?
|
| Blood Urea Nitrogen | 1 | 2005 | 12 | 0.060 |
Why?
|
| Nitrogen | 1 | 2005 | 10 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 98 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 73 | 0.060 |
Why?
|
| Necrosis | 1 | 2005 | 53 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 167 | 0.060 |
Why?
|
| Homeostasis | 2 | 2016 | 132 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2004 | 40 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 39 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 80 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 62 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2005 | 290 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 62 | 0.060 |
Why?
|
| Pseudomonas | 1 | 2003 | 6 | 0.060 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2003 | 6 | 0.060 |
Why?
|
| Receptors, Transferrin | 1 | 2003 | 10 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 65 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2003 | 66 | 0.060 |
Why?
|
| Protein Binding | 1 | 2004 | 201 | 0.060 |
Why?
|
| Astrocytoma | 1 | 2003 | 29 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 88 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2003 | 104 | 0.050 |
Why?
|
| Kinetics | 1 | 2003 | 208 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 288 | 0.050 |
Why?
|
| Immune Tolerance | 2 | 2014 | 71 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2003 | 134 | 0.050 |
Why?
|
| Liver | 1 | 2005 | 484 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2003 | 154 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 308 | 0.050 |
Why?
|
| Kidney | 1 | 2005 | 518 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 2014 | 123 | 0.040 |
Why?
|
| Time Factors | 1 | 2005 | 2145 | 0.040 |
Why?
|
| Nucleotides | 1 | 2019 | 16 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 17 | 0.040 |
Why?
|
| Carnitine | 1 | 2019 | 14 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 68 | 0.040 |
Why?
|
| Amino Acids | 1 | 2019 | 46 | 0.040 |
Why?
|
| Female | 5 | 2015 | 19999 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 105 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2005 | 3304 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 53 | 0.030 |
Why?
|
| Ribosomes | 1 | 2015 | 10 | 0.030 |
Why?
|
| CpG Islands | 1 | 2015 | 45 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 157 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 52 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2014 | 14 | 0.030 |
Why?
|
| Carbazoles | 1 | 2014 | 6 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2014 | 31 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 124 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2014 | 40 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2016 | 229 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 101 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 141 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 71 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2014 | 75 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2014 | 189 | 0.030 |
Why?
|
| Macaca fascicularis | 2 | 2004 | 434 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 33 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 21 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 152 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 263 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 288 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 2009 | 10 | 0.020 |
Why?
|
| Response Elements | 1 | 2009 | 16 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2009 | 27 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 507 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 392 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 3990 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 78 | 0.020 |
Why?
|
| Anorexia | 1 | 2004 | 5 | 0.020 |
Why?
|
| Half-Life | 1 | 2004 | 23 | 0.020 |
Why?
|
| Vasculitis | 1 | 2004 | 24 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 100 | 0.010 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2004 | 2 | 0.010 |
Why?
|
| Drug Stability | 1 | 2004 | 8 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2004 | 43 | 0.010 |
Why?
|
| Plasmids | 1 | 2004 | 48 | 0.010 |
Why?
|
| Haplorhini | 1 | 2004 | 68 | 0.010 |
Why?
|
| Genes, erbB-1 | 1 | 2003 | 15 | 0.010 |
Why?
|
| Injections | 1 | 2003 | 64 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 252 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 283 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 357 | 0.010 |
Why?
|
| Pancreas | 1 | 2003 | 103 | 0.010 |
Why?
|
| Male | 2 | 2015 | 19202 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 279 | 0.010 |
Why?
|
| Gene Expression | 1 | 2004 | 337 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2004 | 201 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 103 | 0.010 |
Why?
|
| Aged | 1 | 2015 | 10308 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 629 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 11834 | 0.010 |
Why?
|